These 3 Biotech Stocks Have MAJOR Catalysts Coming (Get in Before the Move)

Get the FREE Report on 7 Stocks to Buy and Hold Forever: https://www.marketbeat.com/y/yt991/ Three biotech stocks. Three major FDA catalysts. And the results could send these stocks soaring or send them tumbling. MarketBeat analyst Chris Markoch joins Bridget to break down Kodiak Sciences, Capricor Therapeutics, and Invivyd, three small-cap biotechs all approaching binary, high-stakes FDA events. Chris walks through why FDA catalysts move biotech stocks more than almost any other sector, what separates a late-stage phase three trial from an early one, and how to think about institutional ownership and short interest as signals for volatility. The two dig into each company's pipeline, what their trials are actually testing, the price action leading into their next catalyst, and analyst price targets that in some cases point to massive upside if results come in positive. View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. Video Chapters: 0:00 Intro 5:02 Stock 1 10:35 Stock 2 16:00 Stock 3 DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.